{
    "clinical_study": {
        "@rank": "153127", 
        "arm_group": [
            {
                "arm_group_label": "Higher dose icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity."
            }, 
            {
                "arm_group_label": "Routine dose icotinib", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesize that higher dose icotinib is related with better efficacy. The primary\n      objective is to compare the progression-free survival of higher dose and routine dose of\n      icotinib in treating pretreated advanced non-small cell lung cancer patients with stable\n      disease after 8-week routine dose icotinib treatment."
        }, 
        "brief_title": "High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients\n             confirmed by sputum cytology);\n\n          -  Pretreated with at least 1 platinum-based chemotherapy;\n\n          -  No previous targeted treatment such as gefitinib, erlotinib;\n\n          -  With a measurable disease(longest diameters >=10mm with Spiral computed tomography\n             (CT)and >=20mm with conventional CT) according to RECIST Criteria;\n\n          -  WHO performance status(PS)<= 2;\n\n          -  Adequate organ functions;\n\n          -  Signed and dated informed consent before the start of specific protocol procedures.\n\n        Exclusion Criteria:\n\n          -  Allergic to icotinib;\n\n          -  Patients with metastatic brain tumors with symptoms;\n\n          -  Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or\n             small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab;\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027090", 
            "org_study_id": "BD-IC-IV17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Routine dose icotinib", 
                "description": "Icotinib is administered 125 mg three times daily.", 
                "intervention_name": "Routine dose icotinib", 
                "intervention_type": "Drug", 
                "other_name": "Commana"
            }, 
            {
                "arm_group_label": "Higher dose icotinib", 
                "description": "After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.", 
                "intervention_name": "Higher dose icotinib", 
                "intervention_type": "Drug", 
                "other_name": "Commana"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200030"
                }, 
                "name": "Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study", 
        "overall_official": {
            "affiliation": "Shanghai Chest Hospital", 
            "last_name": "Shun Lu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027090"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Response rate assessed using the RECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Adverse events are assessed by Common Terminology Criteria for Adverse Events v4.0", 
                "measure": "The number of patients who suffered adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}